- Home
- EVGO vs CELC Comparison
EVGO vs CELC Comparison
Compare EVGO & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVGO
- CELC
- Stock Information
- Founded
- EVGO 2010
- CELC 2011
- Country
- EVGO United States
- CELC United States
- Employees
- EVGO N/A
- CELC N/A
- Industry
- EVGO Other Specialty Stores
- CELC Medical Specialities
- Sector
- EVGO Consumer Discretionary
- CELC Health Care
- Exchange
- EVGO Nasdaq
- CELC Nasdaq
- Market Cap
- EVGO 325.8M
- CELC 377.8M
- IPO Year
- EVGO N/A
- CELC 2017
- Fundamental
- Price
- EVGO $2.37
- CELC $10.03
- Analyst Decision
- EVGO Strong Buy
- CELC Strong Buy
- Analyst Count
- EVGO 10
- CELC 6
- Target Price
- EVGO $6.11
- CELC $30.17
- AVG Volume (30 Days)
- EVGO 3.7M
- CELC 291.6K
- Earning Date
- EVGO 03-04-2025
- CELC 03-26-2025
- Dividend Yield
- EVGO N/A
- CELC N/A
- EPS Growth
- EVGO N/A
- CELC N/A
- EPS
- EVGO N/A
- CELC N/A
- Revenue
- EVGO $256,825,000.00
- CELC N/A
- Revenue This Year
- EVGO $42.11
- CELC N/A
- Revenue Next Year
- EVGO $30.36
- CELC N/A
- P/E Ratio
- EVGO N/A
- CELC N/A
- Revenue Growth
- EVGO 59.57
- CELC N/A
- 52 Week Low
- EVGO $1.65
- CELC $8.53
- 52 Week High
- EVGO $9.07
- CELC $22.19
- Technical
- Relative Strength Index (RSI)
- EVGO 31.16
- CELC 42.28
- Support Level
- EVGO $2.32
- CELC $9.61
- Resistance Level
- EVGO $2.55
- CELC $10.89
- Average True Range (ATR)
- EVGO 0.20
- CELC 1.08
- MACD
- EVGO 0.02
- CELC 0.03
- Stochastic Oscillator
- EVGO 23.49
- CELC 32.26
Stock Price Comparison Chart: EVGO vs CELC
About EVGO EVgo Inc.
EVgo owns and operates a public direct current fast-charging network in the US. Its network of charging stations provides electric vehicle charging infrastructure to consumers and businesses. The network is capable of charging all EV models and meets all charging standards currently available in the US. EVgo partners with national and regional chains of grocery stores, automotive original equipment manufacturers, hotels, shopping centers, gas stations, parking lot operators, local governments, and independent property owners to locate and deploy its EV charging infrastructure.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.